Showing results (411-420 of 563) with videos related to

Sort By:
Pageof 57
Drug Development Research|July 19, 2017
High Dosage of Vitamin D Regulates the Energy Metabolism and Increases Insulin Sensitivity, but are Associated with High Levels of Kidney DamageRafael Calais Gaspar, José Diego Botezelli, Gabriel Keine Kuga, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 25, 2024
Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial)John Nikitas, Ethan Lam, Kiara Adame Booker, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 3, 2024
Correlation of FAPI PET Uptake with Immunohistochemistry in Explanted Lungs from Patients with Advanced Interstitial Lung DiseaseMasatoshi Hotta, Grace Hyun J Kim, Vilasinee Rerkpichaisuth, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 15, 2024
FAPI PET uptake patterns after invasive medical interventions: a single center retrospective analysisPeter George Maliha, Masatoshi Hotta, Andrea Farolfi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 7, 2019
Mapping Prostate Cancer Lesions Before and After Unsuccessful Salvage Lymph Node Dissection Using Repeat PSMA PETAndrea Farolfi, Harun Ilhan, Andrei Gafita, et al.
European Urology|January 30, 2024
Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774)Wesley R Armstrong, Amar U Kishan, Kiara M Booker, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 2, 2026
Dosimetry Analysis of <sup>177</sup>Lu-PSMA-I&T in Patients with Low-Volume Oligometastatic Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the LUNAR TrialZachary Ells, Catherine Meyer, Koichiro Kimura, et al.
JAMA Network Open|January 3, 2025
PSMA-PET/CT Findings in Patients With High-Risk Biochemically Recurrent Prostate Cancer With No Metastatic Disease by Conventional ImagingAdrien Holzgreve, Wesley R Armstrong, Kevyn J Clark, et al.
European Urology|June 14, 2020
Efficacy and Safety of <sup>177</sup>Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective StudyAndrei Gafita, Wolfgang P Fendler, Wang Hui, et al.
Oral Oncology|July 10, 2017
Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: Pooled analysis of two GORTEC randomized trialsYungan Tao, Anne Aupérin, Pierre Graff, et al.
Pageof 57